How it works:
Sorafenib is a multikinase inhibitor that blocks tumour cell proliferation and angiogenesis by inhibiting intracellular and membrane-bound kinases. It effectively targets both the cancer cells and the blood vessels feeding the tumour.
Recommended for:
Adults with unresectable or metastatic hepatocellular carcinoma
Patients with advanced renal cell carcinoma resistant to interferon therapy
Individuals with differentiated thyroid carcinoma unresponsive to radioactive iodine
To be used only under oncologist supervision
Hepatocellular carcinoma (liver cancer)
Advanced renal cell carcinoma
Differentiated thyroid carcinoma
SORAFENAT is usually taken orally at a dose of 400mg (two 200mg tablets) twice daily, approximately 12 hours apart. Tablets should be swallowed whole with water, either on an empty stomach or with a low-fat meal. Dosage may vary based on patient tolerance and medical guidance.
Hypersensitivity to sorafenib or any of its components
Pregnancy and breastfeeding
Severe liver impairment
Decompensated heart failure
Diarrhoea, appetite loss, nausea
Skin reactions including hand-foot syndrome and rash
Elevated blood pressure
Fatigue and weakness
Hair loss
Thyroid dysfunction
Increased amylase and lipase levels
